Supplementary Table S9 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
Year: 2024
Type: supplementary-materials
Abstract: This dataset summarizes the grade 3 or higher treatment-related adverse events (TRAEs) observed in patients with advanced solid tumors treated in the ongoing phase 1 trial of botensilimab. This safety information is crucial for assessing the risk-benefit profile of botensilimab alone and in combination with balstilimab.
Authors: Dhan Chand, David A. Savitsky, Shanmugarajan Krishnan, Gabriel Mednick, Chloe Delepine, Pilar Garcia-Broncano, Kah Teong Soh, Wei Wu, Margaret K. Wilkens, Olga Udartseva, Sylvia Vincent, Bishnu Joshi, Justin G. Keith, Mariana Manrique, Marilyn Marques, Antoine Tanne, Daniel L. Levey, Haiyong Han, Serina Ng, Jackson Ridpath, Olivia Huber, Benjamin Morin, Claire Galand, Sean Bourdelais, Randi B. Gombos, Rebecca Ward, Yu Qin, Jeremy D. Waight, Matthew R. Costa, Alvaro Sebastian-Yague, Nils-Petter Rudqvist, Malgorzata Pupecka-Swider, Vignesh Venkatraman, Andrew Slee, Jaymin M. Patel, Joseph E. Grossman, Nicholas S. Wilson, Daniel D. Von Hoff, Justin Stebbing, Tyler J. Curiel, Jennifer S. Buell, Steven J. O’Day, Robert B. Stein
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4404933659